The Marked Chart Wire · Business
Moderna
Moderna lifts 2026 outlook after melanoma vaccine success
Moderna raised its 2026 revenue growth target to 15-25 percent and reported that its melanoma vaccine with Merck met Phase 3 endpoints. The company also secured a lower-rate credit facility from Ares Management.
Part of a series: Moderna stock falls on leak, then raises 2026 outlook
